Page 9 - Flipbook

PARPs in Prostate Cancer

PARP Inhibitors are Health Canada Approved or Under Investigation for Prostate Cancer

Olaparib Rucaparib Veliparib Talazoparib Niraparib

MW 434.5 323.4 244.3 380.8 320.4

PARP1 IC 50 5 nM 0.65 nM 1.2 nM 0.56 nM 3.8 nM

PARP2 IC 50 1 nM 0.08 nM 0.41 nM 0.15 nM 2.1 nM

Trapping ++ ++ + ++++ +++

Monotherapy for mCRPC with a
deleterious or suspected deleterious
Approved for prostate BRCA or ATM mutation(germline No No No No
cancer and/or somatic)
Prior treatment with new hormonal
agent*

*Eg, abiraterone, enzalutamide, darolutamide, or apalutamide

mCRPC, metastatic castration-resistant prostate cancer
Carney B et al. Nat Comm 2018;9:176.